THE SYMBOL '***' IS USED THROUGHOUT THIS EXHIBIT TO INDICATE THAT A PORTION OF
THE EXHIBIT HAS BEEN OMITTED AS CONFIDENTIAL
AMENDMENT TO LICENSE AGREEMENT
This Amendment Agreement, dated as of February 27, 2004, is by and between THE UNIVERSITY OF
BRITISH COLUMBIA (the "University") and ANGIOTECH PHARMACEUTICALS, INC. (the
WHEREAS pursuant to a license agreement having a Commencement Date of August 1, 1997 (the
"License Agreement"), University granted to Licensee an exclusive worldwide license to use and to sublicense the
University's rights in and to the Technology and any Improvements (as those capitalized terms are defined in the
WHEREAS University and Licensee are entering into this Amendment Agreement to set out. certain
amendments to the License Agreement mutually agreed to between the parties.
NOW, THEREFORE, in consideration of the mutual promises and agreements set. forth herein, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, University
and Licensee hereby agree as follows:
Capitalized terms not specifically' defined herein shall have the meanings set forth in the License
Agreement. 'Capitalized terms defined herein shall have . the meanings set forth in this Amendment Agreement.
License Agreement Amendments
Amendments. The License Agreement shall be amended as set out with particularity in Schedule
"1" to this Amendment Agreement, and each of University and Licensee covenant and agree to keep, Observe and
perform each and every one of the terms, covenants, agreements and conditions On their part to be kept, observed
or performed under the License Agreement, as supplemented and amended hereby.
Effect of Amendment Agreement. This Amendment Agreement supplements and amends the
'License Agreement, and the License Agreement and this Amendment Agreement shall henceforth be read
'together and sha